Calidi Biotherapeutics shares surge 16.87% premarket after partnering with Matica Bio to advance oncolytic virus manufacturing for IND.

Calidi Biotherapeutics Inc. (CLDI) surged 16.87% in premarket trading following multiple positive developments. The company announced a partnership with Matica Bio, a leader in oncolytic virus manufacturing, to advance its IND application for an oncology candidate, signaling progress in its drug development pipeline. Additionally, Calidi disclosed new data on its lead therapeutic, CLD-401, to be presented at the 2025 SITC Annual Meeting, bolstering investor confidence in its clinical-stage assets. Recent news of a scientific advisory board appointment and a reverse stock split further reinforced strategic momentum. These developments, particularly the Matica collaboration and data presentation, align with the stock’s sharp premarket ascent, reflecting optimism about its pipeline advancements and operational execution.